[SDG] QoQ Cumulative Quarter Result on 30-Jun-2023 [#2]

Stock
[SDG] SD GUTHRIE BERHAD
Announcement Date
23-Aug-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
30-Jun-2023 [#2]
Profit Trend
QoQ- 550.72%
YoY- -70.65%
Quarter Report
Latest QR
Upcoming QR
SDG's Result
SDG's Financial Summary
View:
Show?
Cumulative Result
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Revenue 4,342,000 18,428,000 13,148,000 8,374,000 4,069,000 21,030,000 15,360,000 -56.89%
PBT 346,000 2,752,000 2,357,000 736,000 255,000 3,492,000 2,749,000 -74.85%
Tax -93,000 -719,000 -568,000 -206,000 -147,000 -809,000 -676,000 -73.31%
NP 253,000 2,033,000 1,789,000 530,000 108,000 2,683,000 2,073,000 -75.36%
-
NP to SH 211,000 1,860,000 1,660,000 449,000 69,000 2,488,000 1,926,000 -77.07%
-
Tax Rate 26.88% 26.13% 24.10% 27.99% 57.65% 23.17% 24.59% -
Total Cost 4,089,000 16,395,000 11,359,000 7,844,000 3,961,000 18,347,000 13,287,000 -54.38%
-
Net Worth 17,635,071 17,773,386 18,188,330 17,358,443 16,251,928 16,390,242 16,459,401 4.70%
Dividend
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Div - 1,037,357 618,956 224,760 - 1,109,280 691,571 -
Div Payout % - 55.77% 37.29% 50.06% - 44.59% 35.91% -
Equity
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Net Worth 17,635,071 17,773,386 18,188,330 17,358,443 16,251,928 16,390,242 16,459,401 4.70%
NOSH 6,915,714 6,915,714 6,915,714 6,915,714 6,915,714 6,915,714 6,915,714 0.00%
Ratio Analysis
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
NP Margin 5.83% 11.03% 13.61% 6.33% 2.65% 12.76% 13.50% -
ROE 1.20% 10.47% 9.13% 2.59% 0.42% 15.18% 11.70% -
Per Share
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 62.78 266.47 190.12 121.09 58.84 304.09 222.10 -56.89%
EPS 3.10 26.90 24.00 6.50 1.00 36.00 27.80 -76.80%
DPS 0.00 15.00 8.95 3.25 0.00 16.04 10.00 -
NAPS 2.55 2.57 2.63 2.51 2.35 2.37 2.38 4.70%
Adjusted Per Share Value based on latest NOSH - 6,915,714
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 62.78 266.47 190.12 121.09 58.84 304.09 222.10 -56.89%
EPS 3.10 26.90 24.00 6.50 1.00 36.00 27.80 -76.80%
DPS 0.00 15.00 8.95 3.25 0.00 16.04 10.00 -
NAPS 2.55 2.57 2.63 2.51 2.35 2.37 2.38 4.70%
Price Multiplier on Financial Quarter End Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 -
Price 4.31 4.46 4.28 4.15 4.27 4.65 4.09 -
P/RPS 6.86 1.67 2.25 3.43 7.26 1.53 1.84 140.24%
P/EPS 141.26 16.58 17.83 63.92 427.97 12.93 14.69 351.57%
EY 0.71 6.03 5.61 1.56 0.23 7.74 6.81 -77.81%
DY 0.00 3.36 2.09 0.78 0.00 3.45 2.44 -
P/NAPS 1.69 1.74 1.63 1.65 1.82 1.96 1.72 -1.16%
Price Multiplier on Announcement Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 31/05/24 22/02/24 24/11/23 23/08/23 24/05/23 17/02/23 22/11/22 -
Price 4.27 4.50 4.35 4.32 4.47 4.33 4.33 -
P/RPS 6.80 1.69 2.29 3.57 7.60 1.42 1.95 129.78%
P/EPS 139.95 16.73 18.12 66.54 448.02 12.04 15.55 332.09%
EY 0.71 5.98 5.52 1.50 0.22 8.31 6.43 -76.95%
DY 0.00 3.33 2.06 0.75 0.00 3.70 2.31 -
P/NAPS 1.67 1.75 1.65 1.72 1.90 1.83 1.82 -5.56%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment